Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc (NQ: BEAM )

24.39 -0.09 (-0.39%)
Streaming Delayed Price Updated: 1:17 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 352,366
Open 24.53
Bid (Size) 24.37 (6)
Ask (Size) 24.42 (3)
Prev. Close 24.49
Today's Range 23.33 - 24.71
52wk Range 20.84 - 49.50
Shares Outstanding 79,199,501
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Breaking Down Beam Therapeutics: 5 Analysts Share Their Views
Via Benzinga

Performance

YTD
-11.00%
-11.00%
1 Month
+5.38%
+5.38%
3 Month
-4.30%
-4.30%
6 Month
-1.95%
-1.95%
1 Year
-12.72%
-12.72%

More News

Read More
This Clorox Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday
Via Benzinga
Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial
Via Benzinga
Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics's Earnings: A Preview
Via Benzinga
Deep Dive Into Beam Therapeutics Stock: Analyst Perspectives (6 Ratings)
Via Benzinga
Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting
From Beam Therapeutics
Via GlobeNewswire
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Via Investor's Business Daily
A Closer Look at 5 Analyst Recommendations For Beam Therapeutics
Via Benzinga
Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating
Via Benzinga
3 Gene Editing Stocks with Potential to Transform Medicine
Via InvestorPlace
BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results
From Beam Therapeutics
Via GlobeNewswire
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?
Via Benzinga
IBM Posts Upbeat Earnings, Joins ServiceNow, Helmerich & Payne, RTX, Nasdaq And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Beam Therapeutics Stock Earns RS Rating Jump To 85
Via Investor's Business Daily
Why Is Conn’s (CONN) Stock Down 36% Today?
Via InvestorPlace
Topics Bankruptcy
Exposures Financial Legal
Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40
Via InvestorPlace
Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
3 Gene Editing Stocks Shaping the Future of Medicine
Via InvestorPlace
Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast
Via Benzinga
Beam Therapeutics Announces Transition of Chief Financial Officer
From Beam Therapeutics
Via GlobeNewswire
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.